“Last year we introduced our initiative, Panorama Powered by ProFound AI, and with ProFound AI Risk, this concept is beginning to come to life,” added Mr. Klein. “iCAD continues to bring innovative solutions like this to market, and we look forward to advancing the field of mammography as we are working to further expand the ProFound AI portfolio to include next-generation technology that will also incorporate patient’s prior images.* The ability to correlate patients’ past and present images along with future risk will provide clinicians with a broader panoramic vision for each patient that will enable them to evaluate findings across time and ultimately lead to more tailored and personalized patient care.”
About iCAD, Inc.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.Back to HCB News